Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: Potential contributors to spontaneous recovery from experimental Parkinsonism

Journal of Neuroscience Research

Volumn 65, Issue 3, 2001, Pages 254-266

  Rothblat, David S ^a   Schroeder, J A ^a   Schneider, J S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Dopamine; Retrorubral area; Striatum; Substantia nigra; Ventral tegmental area

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE TRANSPORTER; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAT; CONTROLLED STUDY; CONVALESCENCE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; GENE EXPRESSION; MALE; MESENCEPHALON; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD DORSAL HORN; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CARRIER PROTEINS; CATS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENE EXPRESSION PROFILING; IN SITU HYBRIDIZATION; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MESENCEPHALON; NERVE TISSUE PROTEINS; NEURONS; PARKINSONIAN DISORDERS; REMISSION, SPONTANEOUS; RNA, MESSENGER; TYROSINE 3-MONOOXYGENASE;

EID: 0035424801     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.1149     Document Type: Article

References (61)

1. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: Implications for behavioral recovery from brain injury
2. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
3. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age
4. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain
5. Protein kinase A activity may kinetically upregulate the striatal transporter for dopamine
6. Evidence for volume transmission in the dopamine denervated neostriatum of the rat after a unilateral nigral 6-OHDA microinjection. Studies with systemic D-amphetamine treatment
7. Long-term induction of tyrosine hydroxylase expression: Compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain
8. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon
9. An assessment of the validity of densitometric measures of striatal tyrosine hydroxylase-positive fibers: Relationship to apomorphine-induced rotations in 6-hydroxydopamine lesioned rats
10. Dual character, asynaptic and synaptic, of the dopamine innervation in adult rat neostriatum: A quantitative autoradiographic and immunocytochemical analysis
11. MPTP-induced parkinsonism: Relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys
12. Mesencephalic TH mRNA-reduced expression by blocking axonal transport with colchicine
13. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson disease
14. Tyrosine hydroxylase mRNA in the dopaminergic neurons of young adult and aged mice by in situ hybridization
15. Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurons by drugs
16. Regulation of dopamine transporter mRNA levels in the central nervous system
17. A topographic re-evaluation of the nigrostriatal projections to the caudate nucleus in the cat with multiple retrograde tracers
18. 2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons
19. 3H]mazindol binding sites in rat striatum by dopaminergic agents
20. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: An in situ hybridization study
21. Compartmental origins of striatal efferent projections in the cat
22. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson, Alzheimer with parkinsonism, and Alzheimer disease
23. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy
24. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson disease
25. 18F]GBR 13119 binding to the dopamine uptake site
26. Chronic administration of the selective dopamine uptake inhibitor GBR 12909, but not cocaine, produces marked decreases in dopamine transporter density
27. Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys
28. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic terminals in Parkinson disease
29. Effects of chronic cocaine administration on dopamine transporter mRNA and protein in the rat
30. Lack of dopamine receptor agonist effect on striatal dopamine transporter binding sites
31. Semiquantitative analysis of in-situ hybridization results using IMAGE software: A rapid method for counting reduced silver grains of mRNA-positive cells
32. 11C]WIN-35,428
33. Membrane trafficking regulates the activity of the human dopamine transporter
34. Dopamine transporter binding in rat striatum and nucleus accumbens is unaltered following chronic changes in dopamine levels
35. Chronic lesions differentially decrease tyrosine hydroxylase messenger RNA in dopaminergic neurons of the substantia nigra
36. Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: A model for neuron aging
37. Dopamine transporter gene expression in rat mesencephalic dopaminergic neurons is increased by direct interaction with target striatal neurons in vitro
38. Target cells modulate dopamine transporter gene expression during brain development
39. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium
40. Responses of caudate neurons to stimulation of intrinsic and peripheral afferents in normal, symptomatic and recovered MPTP-treated cats
41. Spontaneous functional recovery from parkinsonism is not due to reinnervation of the dorsal striatum by residual dopaminergic neurons
42. Regional differences in striatal dopamine uptake and release associated with recovery from MPTP-induced parkinsonism: An in vivo electrochemical study
43. Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: Implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomology
44. Neurotoxic effects of N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase inmunohistochemistry
45. Neurochemical evaluation of the striatum in symptomatic and recovered MPTP-treated cats
46. Functional recovery from experimental parkinsonism in cats is accompanied by partial recovery of extracellular but not tissue levels of dopamine in the dorsal lateral caudate nucleus
47. Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism
48. Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Behavior, histology and biochemistry
49. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP
50. Role of vesicular monoamine transporter 2 in recovery from MPTP-induced parkinsonism
51. Lesions of nigrostriatal pathway reduce expression of tyrosine hydroxylase gene in residual neurons of substantia nigra
52. Dopamine transporter mRNA is upregulated in the substantia nigra and the ventral tegmental area of amphetamine-sensitized rats
53. Dopamine transporter messenger RNA in Parkinson disease and control substantia nigra neurons
54. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments
55. Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier
56. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson disease
57. Lack of effect of clorgyline or selegiline on dopamine and serotonin transporters in rat caudateputamen or nucleus accumbens
58. Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications
59. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism
60. Animal models of Parkinsonism using selective neurotoxins: Clinical and basic implications
61. The emergence of the volume transmission concept